The Chainsmokers is the biggest band of our era, well-known for worldwide hit songs such as “Closer” and “Don’t Let Me Down”. It comprises of two partners; Alex Pall and Andrew Taggart, the duo who have taken the music industry by storm. Particularly, they have broken the DJeing norm by Andrew Taggart actually singing alongside outsourced vocalists in an effort to insert vocals to their well-crafted electronic soundscapes. Alex Pall, on the other hand, has recently been in the limelight for acquiring a state-of-the-art home at Hollywood Hills.
The home speaks volumes of Alex Pall’s taste, creativity and hard-work. It was built in the 1930s and it was later renovated to give it a modern touch. Peti Lau, renowned interior décor professional, was tasked by Alex Pall to add magnificence and glamour to the interior of the home. Ms. Lau put her skills and expertise into practice and gave the interior of the house a glamorous look. The Alex Pall’s home is a manifestation of his success and the success of the Grammy-winning DJ duo.
The release of the hit song “Closer” took many by surprise, especially when Andrew Taggart took it to the studio and sang along Halsey, a celebrated artist. In an interview with Mathias Rosenzweig, they disclosed a lot about their career and the direction they are taking.
Back to where it all started, Alex Pall was always passionate about DJeing. He did DJeing around New York City and later, he got a job at an art gallery. This is where he met someone who introduced him to Andrew. They were a perfect match and started their music career together.
According to Alex Pall, they have kept re-evaluating themselves, trying new things, discovering themselves and finding themselves, what he said has kept them going. They now create music that people across all ages can relate to in a deep level. They literally write lyrics or rather contribute in writing them, in a move that sees them write about their real-life experiences. Alex Pall and his partner Andrew Taggart are dedicated to create music that impacts the life of people positively.
For over 20 years Dr. Scott Rocklage has been involved with companies on the cutting-edge of the latest biomedical technologies and treatments. Currently he is managing partner of 5AM Ventures, a venture capital firm which provides funding for companies involved in early stage life science related projects. Dr. Rocklage is constantly studying the latest ideas and concepts in life science and working to help physicians and scientists transform their ideas into effective medicines for treating the most devastating medical conditions of our time.
Dr. Rocklage has been in the forefront of medical and scientific research for many years. While working on his Ph.D. in Chemistry at the Massachusetts Institute of Technology, he conducted research in the lab of Richard R. Schrock, the 2005 Nobel Prize winner in Chemistry. And the latest scientific developments still excite Scott Rocklage. Currently the biomedical developments in cancer prevention, diagnosis and treatment have captured his interest. He is excited by the potential of the advances being made in targeted techniques and technologies aimed at specific genotypes and mutations in cancer patients as innovative, new ways to destroy cancerous cells and improve treatment outcomes.
Since getting his undergraduate degree in chemistry from UC Berkley and his Ph.D. from MIT, Dr. Rocklage has been deeply involved in medical research and the healthcare industry. He helped get U.S. FDA approval for the groundbreaking new drugs Teslascan®, Cubicin® and Omniscan™. He has also played a seminal role in getting clinical trials started for six drug candidates. Dr. Rocklage has also held leadership positions in a large number of biotech and biomedical companies and has provided them with the guidance and support they need to succeed.
Dr. Scott Rocklage has held executive leadership or directorial board positions with Cubist Pharmaceuticals, Nycomed Salutar and Nycomed Interventional. He also worked with Salutar and Catalytica doing research and development. While serving as 5AM Ventures’ managing partner and working with their portfolio management team, Dr. Rocklage is also on the directorial boards of WaveRx, Pulmatrix, Variation, Semprus, Achaogen, Relypsa, Ilypsa and Miikana. He’s also on the board of associates of the Whitehead Institute.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.